128
Participants
Start Date
May 2, 2023
Primary Completion Date
June 27, 2025
Study Completion Date
November 30, 2025
Tonabersat
Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
Placebo
Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
Retina-Vitreous Surgeons of Central NY, PC, Liverpool
Pittsburg Clinical Trial Consortium, Sewickley
The Trustees of the University of Pennsylvania, Philadelphia
Elman Retina Group, Baltimore
Hilton Head Retina Institute, Hilton Head Island
Thomas Eye Group, Sandy Springs
Southeast Retina Center, Augusta
University of Florida- Jacksonville, Jacksonville
Southeast Eye Institute, P.A. dba Eye Associates of Pinellas, Pinellas Park
Central Florida Retina Institute, Lakeland
Florida Retina Consultants, Lakeland
National Ophthalmic Research Institute, Fort Myers
Midwest Eye Institute, Indianapolis
Mayo Clinic, Rochester
Illinois Retina Associates, Oak Park
Retina Research Institute, LLC, St Louis
Joseph E. Humble and Raymond Haik PTRS DBA Eye Assoc of Northeast Louisiana, West Monroe
Retina Consultants of Texas, PA, Bellaire
Retinal Consultants of Texas, San Antonio
Texas Retina Associates, Lubbock
Macula Retina Vitreous Institute, Torrance
Southern California Desert Retina Consultants, Inc., Palm Desert
Loma Linda University, Loma Linda
Retina Associates of Southern California, Huntington Beach
East Bay Retina Consultants, Inc., Oakland
Verum Research LLC, Eugene
Boston Medical Center Corporation, Boston
Joslin Diabetes Center, Boston
Lead Sponsor
Collaborators (1)
National Institutes of Health (NIH)
NIH
National Eye Institute (NEI)
NIH
Juvenile Diabetes Research Foundation
OTHER
Jaeb Center for Health Research
OTHER